RxDoctor Payments Data

Jessica Fink, DPM

Foot & Ankle Surgery · Florence, SCNPI 1619350162

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (42.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Peerless Surgical Inc. at 25.6% of the total. Reporting peaked in 2020 at $1,916 and has fallen 73.2% since, to $513 in 2025.

$6,819in general payments, 2019–2025

Across 121 payments — averaging $56.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Peerless Surgical Inc.$2K
  • Integra Lifesciences Corporation$1K
  • Orthofix Medical, Inc.$1K
  • Stryker$515
  • Treace Medical Concepts, Inc.$340
  • Amgen$247
  • plus $2K from 27 others

What the payments were for

  • Travel & lodging$2,18832%
  • Food & beverage$2,88742%
  • Education$1,74326%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,819 in reported general payments places this provider in the 65th percentile of 87 foot & ankle surgery providers in South Carolina.

See all foot & ankle surgery providers in South Carolina

Medicare billing

Part B allowed, 2024
$373,345
Medicare patients
554
Services billed
4,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole22$20,845
SantylCollagenase Clostridium Hist.12$5,428
Ketoconazole142$3,065
Clotrimazole86$2,794
Ciclopirox79$2,469
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip59$1,770
Ammonium Lactate76$1,667
Terbinafine Hcl48$995
Gabapentin85$893
Methylprednisolone94$726
Celecoxib30$455
Etodolac11$441
Diclofenac Sodium21$367
Lidocaine-PrilocaineLidocaine/Prilocaine28$366
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen55$337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$183$5,42812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 87 foot & ankle surgery providers in South Carolina.

Other foot & ankle surgery in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →